PER-001 Implant Shows Functional and Structural Benefits in Diabetic Retinopathy
Overview
PER-001, a novel endothelin antagonist implant, demonstrated safety and significant functional improvement in low-luminance contrast sensitivity and visual field in patients with moderate-to-severe nonproliferative diabetic retinopathy. Structural improvements in retinal ischemia, leakage, and microaneurysms were also observed after a single injection over six months.
Background
Diabetic retinopathy (DR) is a leading cause of vision impairment characterized by retinal ischemia, inflammation, and vascular pathology. Endothelin-1, a potent vasoconstrictor, is upregulated in DR and contributes to disease progression. Current treatments, including anti-VEGF therapies, have limited effects on ischemia and functional outcomes. PER-001 is a first-in-class, long-acting endothelin antagonist delivered via a bio-erodible intravitreal implant designed to block this pathway and improve retinal perfusion.
Data Highlights
| Parameter | Low Dose PER-001 | High Dose PER-001 | Sham Control |
|---|---|---|---|
| Number of Patients | 9 | 9 | 9 |
| DRSS Stability | Stable | Stable | Stable |
| Low-Luminance Contrast Sensitivity Improvement | Improved by 3 dB (15 letters/3 ETDRS lines) | Improved by 3 dB (15 letters/3 ETDRS lines) | No improvement |
| Visual Field | Improved (baseline deficits) | No change (normal baseline) | No change |
| Structural Outcomes (Ischemia, Leakage, Microaneurysms) | Improved | Improved | No improvement |
| Safety | No serious ocular/systemic adverse events | No serious ocular/systemic adverse events | N/A |
| Intraocular Pressure | No change | No change | No change |
Key Findings
- PER-001 was safe and well tolerated with no serious drug-related ocular or systemic adverse events.
- Significant improvement in low-luminance contrast sensitivity by 3 decibels, equivalent to 15 letters or 3 ETDRS lines, was observed in both PER-001 dose groups compared to control.
- Visual field improved in the low-dose group, which had baseline deficits; no change was seen in the high-dose group with normal baseline visual fields.
- Structural improvements in retinal ischemia, leakage, and microaneurysms were demonstrated on ultrawidefield fluorescein angiography in PER-001 treated groups.
- Best corrected visual acuity and diabetic retinopathy severity score remained stable across all groups.
- The implant releases drug steadily over six months and dissolves completely, allowing for potential twice-yearly dosing.
Clinical Implications
PER-001 offers a novel therapeutic approach targeting endothelin-mediated vascular pathology in diabetic retinopathy, addressing ischemia and functional deficits not improved by current treatments. The implant’s six-month duration and favorable safety profile support its potential for twice-yearly administration to preserve or improve visual function. These findings warrant further investigation in larger phase 2b/3 trials to confirm efficacy and long-term benefits.
Conclusion
PER-001 represents a promising first-in-class endothelin antagonist implant that provides both functional and structural improvements in diabetic retinopathy, marking a significant advancement in treatment options. Ongoing and future studies will clarify its role in clinical practice.
References
- Khanani et al. 2025 -- PER-001 Phase 2a Trial Results in Diabetic Retinopathy
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
